Shield Therapeutics Plc (STX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 49,701 | 32,180 | 13,085 | 5,406 | 2,050 |
| Cost of Goods | 26,662 | 17,250 | 9,058 | 2,989 | 1,323 |
| Gross Profit | 23,039 | 14,930 | 4,027 | 2,417 | 727 |
| Operating Expenses | 33,089 | 37,803 | 35,358 | 33,527 | 27,655 |
| Operating Income | -10,050 | -22,873 | -31,331 | -31,111 | -26,928 |
| Interest Expense | 7,415 | 3,873 | 1,016 | 396 | 0 |
| Other Income | 324 | 190 | -28 | -17,001 | 522 |
| Pre-tax Income | -17,141 | -26,556 | -32,375 | -48,507 | -26,406 |
| Income Tax | 514 | 626 | 918 | 438 | -309 |
| Net Income Continuous | -17,655 | -27,182 | -33,293 | -48,945 | -26,097 |
| Net Income | $-17,655 | $-27,182 | $-33,293 | $-48,945 | $-26,097 |
| EPS Basic Total Ops | -0.02 | -0.03 | -0.05 | -0.21 | -0.12 |
| EPS Basic Continuous Ops | -0.02 | -0.03 | -0.05 | -0.21 | -0.12 |
| EPS Diluted Total Ops | -0.02 | -0.03 | -0.05 | -0.21 | -0.12 |
| EPS Diluted Continuous Ops | -0.02 | -0.03 | -0.05 | -0.21 | -0.12 |
| EBITDA(a) | $-8,611 | $-21,258 | $-30,288 | $-45,253 | $-23,427 |